Natera

Natera said that this research collaboration and others will help it clinically validate its circulating tumor DNA assay Signatera. 

The Index gained 4 percent, outperforming the Dow and the Nasdaq, but underperformed the Nasdaq Biotechnology Index, which rose 5 percent.

Natera ran 17 percent more tests in Q2 than it did in the prior-year period, generating $53.6 million in total revenues.

The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.

In a revised medical policy, Aetna said it would continue to cover NIPT for high-risk pregnancies, but not average-risk ones.

The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.

Natera's testing volumes increased but revenues declined due to achieving in-network status with payors and being reimbursed at a lower rate.